Clinical Decision-Making in the Management of Multiple Sclerosis

Author(s):  
Syed A. Rizvi ◽  
Joshua A. Stone ◽  
Saima T. Chaudhry ◽  
Nichola Haddad ◽  
Brian Wong ◽  
...  
2018 ◽  
Vol 89 (6) ◽  
pp. A41.1-A41
Author(s):  
Heidi N Beadnall ◽  
Linda Ly ◽  
Chenyu Wang ◽  
Thibo Billiet ◽  
Annemie Ribbens ◽  
...  

IntroductionQuantitative magnetic resonance imaging (MRI) analysis is currently used in multiple sclerosis (MS) clinical trials. Quantitative MRI (QMRI) data derived using formal analysis techniques is not used in routine MS clinical practice and its effect on clinical decision-making is unknown. The study objective is to explore the influence that QMRI data has on clinical decision-making in real-world MS patients.MethodsClinical MS brain MRI scans (separated by one-year minimum, acquired on the same scanner from the same patient) were evaluated. All patients were on the same disease-modifying therapy (DMT) six months prior to and during the study. QMRI analyses were performed on scan pairs by; imaging analysts using specialised software [semi-automated], and MSmetrix [fully-automated]. Data was presented in two separate reports; local QMRI (semi-automated) and centralised QMRI (MSmetrix). Questionnaires were completed by the same neurologist for each subject using clinical data and standard MRI and QMRI reports.Results31 relapsing-MS patients (77.4% female), with baseline age 42.14 [10.70] years, disease duration 7.68 [4.89] years and EDSS score 1.40 (1.36), were evaluated. Injectable, oral and infusion DMTs were administered in 29.0%, 61.3% and 9.7% of patients respectively. According to questionnaire responses, 83.9% were predicted to have stable disease over the next year based on clinical reports alone and 67.7% with the addition of QMRI report data. DMT change would be considered in 16.1% based on clinical reports and 32.3% with QMRI report inclusion. Earlier clinical ±MRI follow up was considered in 51.6% (MRI only 41.9%;both 9.7%) when QMRI reports were reviewed.ConclusionThis preliminary retrospective study indicates that QMRI report data has the potential to influence clinical decision-making in relapsing-MS patients on DMT regarding disease stability assessment, therapy change contemplation, and consideration of earlier follow-up. This work supports a role for formal QMRI analysis and reporting as a clinical-decision support system in MS.


2018 ◽  
Vol 210 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Francesco Alessandrino ◽  
Anna Pichiecchio ◽  
Giulia Mallucci ◽  
Emanuele Ghione ◽  
Alfredo Romani ◽  
...  

Author(s):  
Stephen Krieger ◽  
Ilana Katz Sand ◽  
Svenja Oynhausen ◽  
Aaron Miller

This chapter covers important historical, scientific, and current issues in the development of modern clinical trials as well as therapeutic interventions for patients with multiple sclerosis. The chapter includes a review of terminology, methodology, and outcomes employed in clinical trials related to multiple sclerosis. A focus of the chapter is on the limitations of historical and current trial designs, particularly in regard to their application to clinical decision making. This second edition incorporates findings from clinical trials of oral agents and monoclonal antibodies developed for treatment of multiple sclerosis and provides an update on ethical issues in multiple sclerosis clinical research.


2011 ◽  
Vol 20 (4) ◽  
pp. 121-123
Author(s):  
Jeri A. Logemann

Evidence-based practice requires astute clinicians to blend our best clinical judgment with the best available external evidence and the patient's own values and expectations. Sometimes, we value one more than another during clinical decision-making, though it is never wise to do so, and sometimes other factors that we are unaware of produce unanticipated clinical outcomes. Sometimes, we feel very strongly about one clinical method or another, and hopefully that belief is founded in evidence. Some beliefs, however, are not founded in evidence. The sound use of evidence is the best way to navigate the debates within our field of practice.


Sign in / Sign up

Export Citation Format

Share Document